Navigation Links
InNexus Biotechnology Strengthens Patent Team With New Leadership

BRITISH COLUMBIA, Canada, Sept. 9 /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (TSX: IXS.V, OTC Bulletin Board: IXSBF,, a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, welcomes David Warden to its Board of Directors.

Mr. Warden was a founding partner of Yetter, Warden & Coleman, L.L.P. In his 23 years of practice, he has represented both plaintiffs and defendants in cases pertaining to antitrust, securities violations, trade secrets, patents, and other business and technology litigation.

"I am pleased to have David join our team as a director on our Board," said Jeff Morhet, Chairman and CEO. "His broad legal experience and, in particular, his expertise in patent law will prove valuable as we continue to expand and fortify our intellectual property position. I look forward to working with David as a valuable addition to our Board."

Mr. Warden is considered one of Houston's top Lawyers from H magazine and recognized as one of the Texas "Super Lawyers" in Texas Monthly magazine from 2003-2006. Warden has published many articles during his career, "Trade Secrets and Patents: Comparison and Contrasts in Royalty Determination," and "How to Quantify Trade Secrets Theft," are among them. He received his B.S. and his M.S. in Engineering from Purdue University and obtained his Juris Doctorate degree in 1981 from the University of Virginia.

InNexus has taken deliberate steps to enhance its intellectual property position. This latest addition follows a previous appointment of Gilbert Gabo, as the company's Vice President of Operations and Director of Legal Affairs. Mr. Gabo was a practicing patent attorney with the law firm of Gifford, Krass, Sprinkle, Anderson & Citkowski, P.C. before joining the company and also brings a decade of operations experience from his work as a product engineer. He received his J.D. in 2001 from the University of Detroit Mercy Law School and his B.S. in Engineering in 1993 from the University of Michigan in Ann Arbor.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL(TM) technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL(TM) antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control that may cause actual results or performance to differ materially from those currently anticipated in such statements.

SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
2. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
3. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
4. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
5. New White Paper Details Strategies for Biotechnology Companies to Improve EH&S Compliance
6. Thomson Scientific to Host Pharmaceutical Vision - A Users Conference for Information, Regulatory Affairs, Competitive Intelligence and Biotechnology Professionals
7. Lixte Biotechnology Holdings, Inc. Announces the Initial Trading of Its Common Stock Under the Symbol: LIXT
8. Luminex Corporation to Present at Biotechnology Industry Organization Investor Forum
9. An Uncommon Eye: Photography Exhibit by Biotechnology Executive at BHCC Gallery
10. Onyx Pharmaceuticals to Present at Biotechnology Industry Organization Investor Forum
11. Leading Biotechnology Company Grows with StayinFront CRM
Post Your Comments:
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... CA (PRWEB) , ... June 23, 2016 , ... ... software, is exhibiting at the Pennsylvania Convention Center and will showcase its product’s ... conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: ... banks to provide their customers enhanced security to ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
Breaking Biology News(10 mins):